Companies /Healthcare

Compugen Ltd

NASDAQ: CGEN Biotechnology

CGEN at a Glance

Valuation
Market cap
$198.9M
P/E ratio
5.4
Profitability
Revenue (TTM)
$75.9M
Profit margin
47.9%
EPS (TTM)
$0.39
Price
52-week range
$1 – $3
Street target
$4.80

Headquartered in Azrieli Center, Holon Fiscal year ends December NASDAQ: CGEN cgen.com

About Compugen

Compugen Ltd. is a clinical-stage cancer immunotherapy company that uses Unigen™, its AI-powered computational discovery platform, to identify novel drug targets and develop immuno-oncology therapeutics. Unigen has produced three targets that reached the clinic: TIGIT, PVRIG and IL-18BP. In October 2026 the company introduced UnigenX™, which extends the platform to tumor-associated antigens and target pairs for targeted immune activation modalities such as T cell engagers.

Its pipeline has three clinical assets:
- **COM701**: a wholly owned, potential first-in-class anti-PVRIG antibody in the fully enrolled, blinded, placebo-controlled MAIA-ovarian trial. It is being tested as maintenance monotherapy in relapsed platinum-sensitive ovarian cancer, with results expected by end of Q1 2027.
- **Rilvegostomig**: a PD-1/TIGIT bispecific owned and developed by AstraZeneca, whose TIGIT component derives from Compugen's COM902. It is in 12 Phase 3 trials. Compugen is eligible for up to $195 million in further milestones and mid-single-digit tiered royalties.
- **GS-0321 (formerly COM503)**: an anti-IL-18 binding protein antibody licensed to Gilead and in a Phase 1 trial run by Compugen. Compugen has received $90 million from Gilead and is eligible for up to $758 million in additional milestones plus tiered royalties.

The business model relies substantially on licensing and collaboration revenue; current revenue comes from recognition of the Gilead upfront and milestone payments. Compugen also runs an early-stage immuno-oncology research pipeline. Its shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker CGEN. Updated

Latest Activity

CGENCompugen
Q3 2026
EPS
-$0.06
est -$0.09+$0.03
Revenue
$4M
est $975K+$3M

A $117.5 million cash position funds operations into 2029, after Gilead upfront and IND milestone recognition more than doubled revenue year over year and came in 291.9% above consensus. That takes financing risk off the table ahead of fully enrolled MAIA-ovarian results for COM701 due by the end of Q1 2027, a binary readout for a $186 million market cap.

Quarterly EPS — reported vs estimate
Earnings on deck — Nov 9–13
601 companies248 before open353 after close

601 companies report next week, and Monday alone front-loads the power trade: Constellation Energy, NRG and Fervo Energy all deliver before the open, alongside KKR, Barrick Mining and monday.com. Data center electricity demand gets its clearest read of the quarter.

  • CEGConstellation Energy CorporationMon Nov 9Before open
  • MNDYmonday.com Ltd.Mon Nov 9Before open
  • NRGNRG Energy, Inc.Mon Nov 9Before open
  • SBETSharplink, Inc.Mon Nov 9Before open
  • VRTSVirtus Investment Partners, Inc.Mon Nov 9Before open
  • BBarrick Mining CorporationMon Nov 9Before open
  • CEVACeva, Inc.Mon Nov 9Before open
  • CGENCompugen Ltd.Mon Nov 9Before open
  • IONSIonis Pharmaceuticals, Inc.Mon Nov 9Before open
  • UNITUniti Group Inc.Mon Nov 9Before open
  • FRVOFervo Energy CompanyMon Nov 9Before open
  • HRTXHeron Therapeutics, Inc.Mon Nov 9Before open
  • KGSKodiak Gas Services, Inc. Mon Nov 9Before open
  • KKRKKR & Co. Inc.Mon Nov 9Before open
  • KSPIJoint Stock Company Kaspi.kzMon Nov 9Before open

CGEN Coverage

Frequently Asked Questions

What does Compugen do?

Compugen Ltd. is a clinical-stage cancer immunotherapy company that uses Unigen™, its AI-powered computational discovery platform, to identify novel drug targets and develop immuno-oncology therapeutics. Unigen has produced three targets that reached the clinic: TIGIT, PVRIG and IL-18BP.

What is the CGEN stock price target?

The Wall Street consensus 12-month price target for CGEN is $4.80.